News
RPTX
2.650
0.00%
0.000
Repare Therapeutics completes acquisition and goes private
TipRanks · 01/28 22:32
*News On Repare Therapeutics Inc. (RPTX) Now Under XEN.XX
Dow Jones · 01/28 22:08
Repare Therapeutics Completes Acquisition by XenoTherapeutics
Reuters · 01/28 22:01
NASDAQ TRADE HALT <RPTX.O> TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Reuters · 01/28 00:50
Weekly Report: what happened at RPTX last week (0119-0123)?
Weekly Report · 01/26 09:23
Weekly Report: what happened at RPTX last week (0112-0116)?
Weekly Report · 01/19 09:26
Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics
Reuters · 01/16 22:11
Repare Therapeutics Receive Shareholders Approval Of Its Acquisition By XenoTherapeutics
Benzinga · 01/16 22:01
Repare Therapeutics Inc. Held Shareholder Meeting
Reuters · 01/16 21:58
REPARE SHAREHOLDERS APPROVE ACQUISITION BY XENOTHERAPEUTICS, INC.
Reuters · 01/16 21:58
Press Release: Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
Dow Jones · 01/16 21:58
Weekly Report: what happened at RPTX last week (0105-0109)?
Weekly Report · 01/12 09:25
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million
TipRanks · 01/05 15:08
Weekly Report: what happened at RPTX last week (1229-0102)?
Weekly Report · 01/05 09:24
Repare Therapeutics Sells RP-3467 Program to Gilead
TipRanks · 12/29/2025 12:34
XenoTherapeutics to Acquire All Outstanding Shares of Repare Therapeutics
Reuters · 12/29/2025 12:01
Weekly Report: what happened at RPTX last week (1222-1226)?
Weekly Report · 12/29/2025 09:23
Repare Sells Key Oncology Asset to Gilead, Lifts Expected Xeno Deal Payout
TipRanks · 12/26/2025 21:05
Wednesday Sector Leaders: Drugs, Biotechnology Stocks
NASDAQ · 12/24/2025 17:17
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million
Benzinga · 12/24/2025 13:36
More
Webull provides a variety of real-time RPTX stock news. You can receive the latest news about Repare Therapeutics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RPTX
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.